Investigation of the prognosis for recurrent mandibular dislocation 6 years after autologous blood injection (ABI) therapy

Abstract

We investigated the progress of treatment for recurrent mandibular dislocation 6 years after autologous blood injection (ABI) therapy. We examined 18 patients who had received initial ABI treatment more than 6 years earlier. Fourteen of them had concomitant systemic disease. Seven of the patients (39%) had died, 7 (39%) were still alive, and 4 (22%) could not be located. Of the 7 patients who were still alive and could be located, 4 (86%) had no recurrence. We concluded that ABI therapy was minimally invasive and effective for treatment of recurrent TMJ dislocation. This treatment is safe and especially appropriate for patients with unfavorable medical conditions. Shika Igaku (J Osaka Odontol Soc) 2021; Mar; 84(1):7‐11.